Partnership to Create Enhanced, Customized Computer-Aided Detection Technology for GE Senographe Systems
NASHUA, N.H. and WAUKESHA, Wis., Nov. 21 /PRNewswire-FirstCall/ — iCAD(R), Inc. (NASDAQ:ICAD) , an industry-leading provider of Computer-Aided Detection (CAD) solutions and GE Healthcare, a division of GE (NYSE:GE) , a manufacturer of Senographe(R) Full-Field Digital Mammography (FFDM) systems, today announced an agreement to develop a customized version of iCAD’s SecondLook(R) Digital specific to GE’s Senographe and Seno Advantage family of systems.
This next generation CAD system is designed to enhance the overall clinical performance with Senographe and Seno Advantage systems, specifically improving sensitivity to breast cancer imaging, enhancing usability and workflow as well as providing diagnostic support tools.
“In an effort to provide leading solutions for our customers, GE has selected iCAD as our development partner for digital mammography CAD solutions,” said David Caumartin, general manager of global mammography for GE Healthcare. “iCAD’s currently available revision of SecondLook Digital works well with GE’s complete line of Senographe FFDM systems and Seno Advantage Review Work Stations and will continue to be a key aspect to the company’s platform in an effort to provide the best technology with outstanding clinical value to our customers.”
SecondLook Digital offers radiologists CAD technology that is designed to distinguish cancers from other anomalies in the breast. In addition to workflow advantages, SecondLook Digital detects up to 72% of actionable missed cancers an average of 15 months earlier and integrates seamlessly with DICOM systems.
“We are very pleased to expand our partnership with GE Healthcare to optimize SecondLook Digital with Senographe and Seno Advantage,” said Ken Ferry, president and CEO of iCAD. “By customizing iCAD’s technology for GE’s systems, currently used in leading radiology centers worldwide, we believe that we will increase the many benefits of this system for radiologists, and ultimately provide an even higher level of detection for women.”
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest. GE Healthcare’s broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new “early health” model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE:GE) . Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at http://www.gehealthcare.com/.
About iCAD, Inc.
iCAD, Inc. (NASDAQ:ICAD) is an industry-leading provider of Computer- Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by almost one thousand women’s healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com/.
For iCAD Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at icad@lhai.com
For iCAD Public Relations, contact Kaitlin Ambrogio of Schwartz Communications at 781-684-0770 or via email at icad@schwartz-pr.com
For GE Healthcare Public Relations, contact Arvind Gopalratnam at 262-501-0777 or via email at arvind.gopalratnam@ge.com
“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute “forward- looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward- looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.
First Call Analyst:
FCMN Contact: kambrogio@schwartz-pr.com
Source: iCAD, Inc.; GE Healthcare
